Short Interest in 180 Life Sciences Corp. (NASDAQ:ATNF) Declines By 50.4%

180 Life Sciences Corp. (NASDAQ:ATNF) was the target of a large decrease in short interest in February. As of February 15th, there was short interest totalling 25,900 shares, a decrease of 50.4% from the January 31st total of 52,200 shares. Based on an average trading volume of 409,700 shares, the short-interest ratio is currently 0.1 days. Currently, 1.5% of the shares of the stock are short sold.

Hedge Funds Weigh In On 180 Life Sciences

A hedge fund recently bought a new stake in 180 Life Sciences stock. Rathbones Group PLC purchased a new position in 180 Life Sciences Corp. (NASDAQ:ATNF) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 69,995 shares of the company’s stock, valued at approximately $127,000. Rathbones Group PLC owned 2.20% of 180 Life Sciences at the end of the most recent reporting period. 4.07% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of 180 Life Sciences in a research note on Wednesday, February 19th.

180 Life Sciences Stock Performance

180 Life Sciences stock traded up $0.13 during midday trading on Monday, reaching $1.30. The stock had a trading volume of 470,908 shares, compared to its average volume of 806,975. The company has a fifty day moving average of $1.57 and a 200 day moving average of $2.09. 180 Life Sciences has a 52-week low of $1.10 and a 52-week high of $17.75.

180 Life Sciences Company Profile

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.